Editing Imagen

==Summary==

The success rate for cancer drug development is ~5%. Imagen has pioneered an automated, sophisticated algorithmic technique - to date modelling >150,000 patient treatment data points, which is now being used to accelerate the drug development process and reduce failure. Historically ~£3m raised.

* Founded and led by ex-AstraZeneca scientist in cell biology
* Building unique biobank via unparalleled access to patients and data
* Advisors from Imperial (London), Christie Hospital (Manchester) & big pharma 
* Oncology is largest global pharma market (~$200 billion by 2026)

==Idea==

<html>
<iframe width="560" height="315" src="https://player.vimeo.com/video/425812793?h=be13154d97" frameborder="0" allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture" allowfullscreen></iframe>
</html>

We aim to benefit patients by revolutionising cancer research for pharma.

Our unique innovative platform aims to identify the most effective cancer treatments, helping to deliver personalised, life-changing medicines.

Every cancer is genetically unique, making it difficult for oncologists to predict which treatments to select & which to avoid. Imagen can test 1000's of individual tumours across a wide range of cancer drugs in-vitro, aiming to predict which are most likely to be effective.

Imagen has fully developed its proprietary predictRx assay, enabling oncologists to refer patients to Imagen. This is creating a source of tumour samples to which industry does not have access, allowing Imagen to expand into the pharma sector by satisfying its unmet demand for patient-derived cancer models.

In early-stage drug development, companies must use pre-clinical 'models' that closely resemble real patients, but few such models with patient-relevant data are available. This scarcity contributes to the high drug development failure rate (~95%), which Imagen is addressing by developing 1000's of patient-derived cancer models using its global access to patients.

We require capital to scale our infrastructure with the aim of creating the world's leading Biobank of clinically relevant patient-derived cancer models whilst building the most comprehensive big data set available in cancer research.

==Team==

Geoff Muckle – CEO

Geoff is a market leader in commercialising oncology diagnostics and brings 20 years’ experience in the Pharmaceutical Industry. He has successfully grown companies, built and led sales and business development teams, and been involved in developing many new potential cancer drugs.

Geoff is a successful business leader and is passionate about delivering value to patients, clients and shareholders.

Gareth Griffiths PhD – Chief Scientific Officer

Gareth co-founded Imagen following senior scientific roles in AstraZeneca, with the vision of developing an accurate method of modelling cancer tumour in the lab. He is an innovator in his field having developed and patented various assay development methods and is a respected expert in cell biology.

Gareth is passionate about translating science into outcomes for patients and is responsible for leading the scientific strategy and implementation at Imagen.

Jonathan Engler – Chairman

Jonathan, a qualified doctor and barrister, is a successful entrepreneur with a proven ability to develop, scale and sell companies in the medical field. He leads the Board and is a present and integral member of the leadership team. After co-founding ClinPhone in 1993 - which grew in value to £46m by 2004 before being listed at a value of around £100m, he invested in Imagen. He also sits on the Board of other high growth healthcare companies.